Literatur
- 1
Calfee. et al .
Safety and efficacy of intravenous zanamivir
in preventing experimental human influenza A virus infection.
Antimicrob
Agents Chemother.
1999;
43
1616-1620
- 2
Fenton. et
al .
Chemoprophylaxis of influenza A virus infections,
with single doses of zanamivir, demonstrates that zanamivir is cleared
slowly from the respiratory tract.
Antimicrob Agents Chemother.
1999;
43
2642-2647
- 3
Hayden. et
al. Zanamivir Family Study Group .
Inhaled zanamivir
for the prevention of influenza in families.
N Engl J
Med.
2000;
343
1282-1289
- 4
Hayden. et
al .
Use of the oral neuraminidase inhibitor oseltamivir
in experimental human influenza: randomized controlled trials for
prevention and treatment.
JAMA.
1999;
282
1240-1246
- 5
Hayden. et
al .
Use of the selective oral neuraminidase inhibitor
oseltamivir to prevent influenza.
N Engl J Med.
1999;
341
1336-1343
- 6
Jefferson. et
al .
Neuraminidase inhibitors for preventing and treating
influenza in healthy adults.
Cochrane Database Syst Rev.
2000;
2
CD001265
- 7
Kim C U. et al .
Neuraminidase inhibitors as anti-influenza
virus agents.
Antivir Chem Chemother.
1999;
10
141-154
- 8
Lalezari J, Campion K, Keene O, Silagy C.
Zanamivir for the treatment
of influenza A and B infection in high-risk patients: a pooled analysis of
randomized controlled trials.
Arch Intern Med.
2001;
161
212-217
- 9
Leneva. et
al .
The neuraminidase inhibitor GS4104 (oseltamivir
phosphate) is efficacious against A/Hong Kong/156/97
(H5N1) and A/Hong Kong/1074/99 (H9N2)
influenza viruses.
Antiviral Res.
2000;
48
101-115
Korrespondenz
Dr. M. Waizmann
Dr. Th Grünewald
Städt. Klinikum »St. Georg« Leipzig 2.
Klinik für Innere Medizin
Delitzscher Straße 141
04129 Leipzig
